Fundraising Fox
Zena Therapeutics
Princeton, US · Founded 2021 · Delaware corporation · 1 known investors
Find your way into Zena Therapeutics
120 people in our graph share verified history with the Zena Therapeutics team — schools, employers, funds. One of them is your warm intro.
Elisa Miller-Outunlockedknows Eileen Carry, PhD · together at National Science Foundation (overlapped)
×11knows the team · via National Science Foundation
Zena Therapeutics is a therapeutics company developing drug candidates, with work spanning molecular design, pharmacology, animal studies, and clinical trial design toward IND submission. The company is led by a scientific leadership and research team supported by pharmacology and clinical consultants and advisors.
Founders & leadership
Zena Therapeutics was founded in 2021 by Eileen Carry, PhD.
EC
Eileen Carry, PhDFounder · Chief Scientific OfficerEileen Carry holds a PhD from Rutgers, where her doctoral research focused on GABA-A receptor modulators for anxiety and withdrawal. She founded Zena Therapeutics and serves as Chief Scientific Officer, leading preclinical development of benzodiazepine alternatives and securing NIH/NIDA funding for the program.
EC
Eileen CarryChief Scientific Officer | co-Founder
AV
Ariane VasilatisChief Executive Officer | co-Founder
Investors · 1
Reported raises · per SEC filings
Form D private placements$500K disclosed across 1 round · 2023
▶$500KraisedSep 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$500KraisedSep 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eileen CarryExecutive Officer, Director
- Ariane VasilatisExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Atsenatx13 shared keywordsAtsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases that cause vision loss. The company focuses on genetic medicines for conditions with limited approved therapies, utilizing proprietary AAV technology platforms.
Zenas Biopharma11 shared keywordsZenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor. Its products are aimed at patients with multiple autoimmune conditions with unmet medical needs.
Sionnatx8 shared keywordsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Robinhood8 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha8 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Zehnatx7 shared keywordsZehna Therapeutics is an early-stage biotech company developing non-bactericidal small-molecule inhibitors of gut microbial enzymes, with lead compounds targeting CutC lyase to lower TMAO levels. Its work focuses on treating cardiometabolic and chronic diseases, with chronic kidney disease as its lead indication.
Abzena7 shared keywordsAbzena is an integrated CDMO and CRO providing end-to-end development and cGMP manufacturing services for complex biologics and bioconjugates, including ADCs, AOCs, bispecifics, and HPAPIs. It serves biotech, academic, and pharmaceutical customers across the drug development lifecycle from discovery through commercial manufacturing.
StockTwits6 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies competing with Zena Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Zena Therapeutics do?
- Zena Therapeutics is a therapeutics company developing drug candidates, with work spanning molecular design, pharmacology, animal studies, and clinical trial design toward IND submission. The company is led by a scientific leadership and research team supported by pharmacology and clinical consultants and advisors.
- Who founded Zena Therapeutics?
- Zena Therapeutics was founded by Eileen Carry, PhD in 2021.
- Who are Zena Therapeutics's investors?
- Zena Therapeutics's investors include Foundation Venture Capital Group, LLC.
- How much funding has Zena Therapeutics raised?
- Zena Therapeutics has disclosed $500K raised across 1 round.
- Where is Zena Therapeutics headquartered?
- Zena Therapeutics is headquartered in Princeton, US.